Bernard R. Bendok, M.D.

Closed for Enrollment

• A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients with Newly Diagnosed or Recurrent Meningiomas Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to investigate  the safety, diagnostic performance, and clinical  usefulness of  the imaging  agent Gleolan™ (Aminolevulinic  Acid Hydrochloride, ALA HCl, ALA, 5-ALA), an orally administered imaging agent for the real-time detection and visualization of meningiomas during tumor resection surgery. ALA is a prodrug that is metabolized  intracellularly  to  form  the  fluorescent  molecule  Protoporphyrin  IX  (PpIX). 

• Assessing Patient-Specific Anatomy with Holography/Augmented Reality and 3D Printing in Patient Education Scottsdale/Phoenix, Ariz.

  The purpose of this study is to assess if using holography/ Augmented Reality and 3D-printed models to visualize intracranial diseases and aid in patient education.

• Feasibility Study Comparing the Utility of GLOW800 and FL800 Intraoperative ICG-VA Tools for Intracranial Lesions Scottsdale/Phoenix, Ariz.

  The purpose of this study is to comparatively evaluate the use of the GLOW800 visualization tool for ICG-VA versus the standard of care visualization tool FL800.